Time course of cerebrospinal fluid responses to antiretroviral therapy: evidence for variable compartmentalization of infection.
about
Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatmentHIV Associated Neurocognitive DisordersCompartmentalized human immunodeficiency virus type 1 originates from long-lived cells in some subjects with HIV-1-associated dementiaGenetic composition of human immunodeficiency virus type 1 in cerebrospinal fluid and blood without treatment and during failing antiretroviral therapy.Compartmentalized human immunodeficiency virus type 1 present in cerebrospinal fluid is produced by short-lived cells.Simian immunodeficiency virus replicates to high levels in naturally infected African green monkeys without inducing immunologic or neurologic disease.Increased human immunodeficiency virus type 1 (HIV-1) env compartmentalization in the presence of HIV-1-associated dementiaQuantitation of human immunodeficiency virus type 1 RNA in different biological compartments.Evolving character of chronic central nervous system HIV infection.Impact of short-term combined antiretroviral therapy on brain virus burden in simian immunodeficiency virus-infected and CD8+ lymphocyte-depleted rhesus macaques.HIV-1 replication in the central nervous system occurs in two distinct cell types.Emergence of CD4 independence envelopes and astrocyte infection in R5 simian-human immunodeficiency virus model of encephalitis.Central nervous system antiretroviral efficacy in HIV infection: a qualitative and quantitative review and implications for future research.Human immunodeficiency virus type 1 (HIV-1) quasispecies at the sites of Mycobacterium tuberculosis infection contribute to systemic HIV-1 heterogeneity.Antiretroviral treatment of central nervous system HIV-1 infection: a review.HIV, dementia and antiretroviral drugs: 30 years of an epidemic.Cerebrospinal fluid human immunodeficiency virus viral load in patients with neurosyphilis.Cross-sectional characterization of HIV-1 env compartmentalization in cerebrospinal fluid over the full disease course.Giant cell encephalitis and microglial infection with mucosally transmitted simian-human immunodeficiency virus SHIVSF162P3N in rhesus macaquesComparative study of methods for detecting sequence compartmentalization in human immunodeficiency virus type 1.Oligodendrocytes Are Targets of HIV-1 Tat: NMDA and AMPA Receptor-Mediated Effects on Survival and Development.The cerebrospinal fluid proteome in HIV infection: change associated with disease severityAntiretroviral treatment effect on immune activation reduces cerebrospinal fluid HIV-1 infectionHIV pharmacology: barriers to the eradication of HIV from the CNS.Antiretroviral therapy and central nervous system HIV type 1 infectionShould antiretroviral therapy for HIV infection be tailored for intracerebral penetration?Quantification of entry phenotypes of macrophage-tropic HIV-1 across a wide range of CD4 densities.Pharmacokinetics and pharmacodynamics of antiretrovirals in the central nervous system.Cerebrospinal Fluid HIV Escape from Antiretroviral Therapy.Transmigration of macrophages across the choroid plexus epithelium in response to the feline immunodeficiency virusGenetic shift of env V3 loop viral sequences in patients with HIV-associated neurocognitive disorder during antiretroviral therapy.Major coexisting human immunodeficiency virus type 1 env gene subpopulations in the peripheral blood are produced by cells with similar turnover rates and show little evidence of genetic compartmentalization.Changes in CSF and plasma HIV-1 RNA and cognition after starting potent antiretroviral therapy.Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations.
P2860
Q24814874-491A3FF1-9813-4A59-B233-43FD9E68EC9FQ27023968-0978A151-BCFA-48DB-B6C3-0B332D729974Q28475360-47BAAD20-05B6-408C-BB4D-DE2BA511DD93Q33716348-390F7D2E-93C1-4EC7-A5C8-CD087AC169EDQ33843510-29E7E03B-9E6D-4315-BE55-0C8463195201Q33850643-B2693C4B-17A6-40CA-B42F-BD7AB78F6D19Q33911855-401FFDBA-CF99-4557-9C58-1568F6A2C939Q33966350-9EE5BCF7-522C-4EB2-ADAC-A56C22FF1C7BQ33995713-B5B3BC95-7AED-4E3F-A69D-76CABE27AE61Q34033558-4CF4A943-3E6C-4515-BF95-C5BF65707B89Q34050421-7D82EE44-C90A-43AA-A010-9616A8F6F3C9Q34057907-C0DA53AE-9BC6-4444-AA49-CEDCAA5EC644Q34080236-119542E1-DE79-4726-A46F-023AA37FA1BEQ34330804-2105E600-1E20-40F0-8E5D-434250CE0CB6Q34459372-A4786804-0F5A-476F-B191-ADC603D69E97Q34573511-4FE57457-AE9A-4C40-9133-4F79D3A3EDF0Q34791743-95BAF083-956C-4E97-B929-F0DB58E9A324Q34950897-8FBD967F-B674-43C4-873E-61059A9B701EQ35110503-8CDE2E71-13B8-4FBD-B586-FE08DCB9E0EDQ35857191-A26C73F9-4428-410E-AF70-B2E504D5E8B3Q35941437-41DA3DBE-2C3D-4671-B589-0127C216C82DQ35965332-DF70CB15-F4F0-42A6-A607-B18E0DA3C019Q36344916-6BD92656-D452-497A-9F63-79396E3617A8Q36552753-2DBD6948-B84F-4392-B2F5-9A6B4EA1459CQ37066982-D7311870-DCF8-4233-9A85-2AA7CF4BAE4FQ37362071-69AC82F2-7389-468A-BB83-161E1D72F94CQ37547061-2B55F921-7FC5-454C-9A4A-772511A2F001Q38247035-285B01E1-9DF7-4402-A548-667F0AA463B5Q38414364-8A1FAB9B-8497-44D7-B170-B85D070F7274Q42114039-E556301D-922E-4133-8B83-D6F89706694CQ42264249-4902ECDA-D805-4CE9-9A7B-D1E5A32B4019Q42928634-0C4DFA88-3627-4461-8C70-6B05D59D8F45Q43125190-7CD62782-2457-49DF-943A-744BC37BC9DDQ43871660-0F38D01B-5B3A-4DA6-9400-CBF9BA1F2EAE
P2860
Time course of cerebrospinal fluid responses to antiretroviral therapy: evidence for variable compartmentalization of infection.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Time course of cerebrospinal f ...... artmentalization of infection.
@en
type
label
Time course of cerebrospinal f ...... artmentalization of infection.
@en
prefLabel
Time course of cerebrospinal f ...... artmentalization of infection.
@en
P2093
P1433
P1476
Time course of cerebrospinal f ...... partmentalization of infection
@en
P2093
S Staprans
T Novakovic-Agopian
P304
P356
10.1097/00002030-199906180-00008
P407
P577
1999-06-01T00:00:00Z